Veraxa Biotech: On the Path to Unicorn Status at NASDAQ

We are delighted to announce a major milestone achieved by one of our tenants at Technologiepark Heidelberg: Veraxa Biotech AG, located at the Business Development Center (BDC) Heidelberg and in Switzerland, is set to go public on the U.S. NASDAQ stock exchange.

Veraxa will merge with the U.S.-listed Voyager Acquisition Corp., a Special Purpose Acquisition Company (SPAC), reaching an approximate valuation of USD 1.64 billion. The transaction could provide the company with up to USD 253 million in new capital.

Veraxa focuses on developing novel cancer therapies, particularly Antibody-Drug Conjugates (ADCs) and T-Cell Engagers (TCEs). With its proprietary BiTAC platform, Veraxa aims to set new standards in oncology: two drug components are only activated together, significantly enhancing treatment safety.

CEO Dr. Christoph Antz and Oliver R. Baumann, CEO of parent company Xlife Sciences AG, see the NASDAQ listing as a key step toward international growth and technological advancement.

The listing, expected in Q4 2025 under the ticker symbol "VERX," would be the first U.S. IPO by a German biotech company since 2020.

We congratulate Veraxa on this outstanding achievement and are proud to support their journey here at Technologiepark Heidelberg.

Please find the full article here.